PP_1170x120_10-25-21

Johnson & Johnson

FDA panel endorses booster shot for J&J COVID vaccine

FDA panel endorses booster shot for J&J COVID vaccine

WASHINGTON — A panel of U.S. health advisers endorsed booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine Friday, saying they should be offered at least two months after immunization. J&J has requested the Food and Drug Administration for flexibility with its booster, arguing the extra dose adds important protection as early as two months after

Johnson & Johnson’s Dr. Paul Stoffels to retire

Johnson & Johnson’s Dr. Paul Stoffels to retire

NEW BRUNSWICK, N.J. — Johnson & Johnson announced that Dr. Paul Stoffels, currently vice chairman of the executive committee and chief scientific officer of Johnson & Johnson, will retire from the company effective December 31, 2021. As the vice chairman of the executive committee and chief scientific officer, Dr. Stoffels spearheaded the company’s research and

J&J to stop selling opioid meds as part of $230M settlement with New York

J&J to stop selling opioid meds as part of $230M settlement with New York

NEW YORK – Johnson & Johnson and its U.S.-based Janssen Pharmaceutical Companies announced  this weekend a settlement agreement with the State of New York and its participating subdivisions, including Nassau County and Suffolk County, resolving their opioid-related claims against the company. With this agreement, the company is removed from the trial scheduled to begin in

FDA confirms Johnson & Johnson vaccine is safe and effective

FDA confirms Johnson & Johnson vaccine is safe and effective

WASHINGTON — According to published reports, the U.S. Food and Drug Administration (FDA) has found the single-shot Johnson & Johnson coronavirus vaccine to be safe and effective. This move paves the way for it to become the third COVID-19 vaccine to be authorised in the US, possibly by tomorrow. The vaccine would be a cost-effective

Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion

Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion

NEW BRUNSWICK, N.J. – Johnson & Johnson  announced that it has entered into a definitive agreement to acquire Momenta Pharmaceuticals (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. The deal provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson

Johnson & Johnson to discontinue talc-based Johnson’s Baby Powder in U.S. and Canada

Johnson & Johnson to discontinue talc-based Johnson’s Baby Powder in U.S. and Canada

NEW BRUNSWICK, N.J. — As part of a portfolio assessment related to COVID-19, in March, Johnson & Johnson Consumer Health announced on Tuesday that it has stopped shipping hundreds of items in the U.S. and Canada to prioritize high-demand products and to allow for appropriate social distancing in manufacturing and distribution facilities during this unprecedented

Johnson & Johnson is a leading candidate for COVID-19 vaccine

Johnson & Johnson is a leading candidate for COVID-19 vaccine

NEW BRUNSWICK, N.J. – Johnson & Johnson has announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of

Johnson & Johnson expands partnership with BARDA

Johnson & Johnson expands partnership with BARDA

NEW BRUNSWICK, N.J. — Johnson & Johnson announced Tuesday that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for

Johnson & Johnson launches multi-pronged response to coronavirus

Johnson & Johnson launches multi-pronged response to coronavirus

NEW BRUNSWICK, N.J. — Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the company has initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others

Tylenol launches first new product in over a decade

Tylenol launches first new product in over a decade

BRUNSWICK, N.J. — For the first time in over ten years, Johnson & Johnson Consumer is introducing the first new form of Children’s Tylenol with the release of Children’s Tylenol Dissolve Packs. The new product is the only pediatric acetaminophen offered in an orally dissolving granular form.   The company said that its consumer research informed

1 2 3